Abbott ABT is facing a challenging business environment globally. Unfavorable foreign exchange impact continues to impede ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

O'Melveny & Myers is defending Abbott Laboratories in a pending class action against the company and two other co-defendants, ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories ( NYSE:ABT) with a Overweight recommendation.

Abbott India said that it has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area, ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...